Previous close | 29.94 |
Open | 29.97 |
Bid | 31.62 x 800 |
Ask | 31.63 x 1100 |
Day's range | 29.67 - 30.01 |
52-week range | 26.32 - 42.99 |
Volume | |
Avg. volume | 645,148 |
Market cap | 19.455B |
Beta (5Y monthly) | 0.76 |
PE ratio (TTM) | 30.93 |
EPS (TTM) | 0.96 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 40.32 |
Company Announcement COPENHAGEN, Denmark; March 18, 2024 – Genmab A/S (Nasdaq: GMAB) announces that its share buy-back program has been completed on March 15, 2024 On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program. The share buy-back program was expected to be completed no later than March 15, 2024, and comprised up to 190,000 shares. The following transactions were executed under the program from M
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World. In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United […]
Company Announcement Repurchase of up to DKK 3.5 billion worth of sharesCompletion expected no later than December 16, 2024 COPENHAGEN, Denmark; March 15, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that it is initiating a share buy-back program. The share buy-back program will be undertaken on the terms set out below and in accordance with Regulation (EU) No. 596/2014 (‘MAR’) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the “Safe Harbour Regulation.” Time fra